KDM2B and glioblastoma: Based on the effects of genetic targeting of KDM2B on chemotherapy sensitivity, we interrogated the potential of GSK‐J4 to sensitize glioblastoma cells to CCNU and VP‐16, by treating cells with GSK‐J4 or chemotherapy alone or in combination with one another, permitting calculation of the combinational index (CI) (Fig. 6A–C).